RT Journal Article
SR Electronic
T1 Biological markers of successful pleurodesis for malignant pleural effusion
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP OA495
DO 10.1183/13993003.congress-2016.OA495
VO 48
IS suppl 60
A1 Ioannis Psallidas
A1 Nikolaos Kanellakis
A1 Marie-Laetitia Thezenas
A1 Philip Charles
A1 John Corcoran
A1 Rob Hallifax
A1 Ambika Talwar
A1 Ahmed Yousuf
A1 John Wrightson
A1 Ian Pavord
A1 Climent Casals Pascual
A1 Benedikt Kessler
A1 Najib Rahman
YR 2016
UL http://erj.ersjournals.com/content/48/suppl_60/OA495.abstract
AB Introduction and objectives: Malignant pleural effusion (MPE) is a rapidly rising healthcare burden and critically hampers the patients' survival and quality of life. Current treatments aim to palliate symptoms and talc pleurodesis remains a standard therapeutic modality. There is little high quality data in prediction of successful pleurodesis and therapeutic biomarkers are desperately needed.Aim: To identify and validate novel therapeutic biomarkers for successful pleurodesis in MPE.Methods: Clinical data and pleural fluid from MPE patients prior to treatment were prospectively collected as part of the randomised TIME2 trial. Patients were classified based on the treatment outcome (success/failure based on study datasets). Pleural fluid on enrolment (Success n=15, Failure n=11) were assessed with mass spectrometry profiling after depletion of the 12 most abundant proteins. Full protein profile analysed with R software and ELISA technique was performed for the validation of the results.Results: Mass spectrometry identified 1,154 proteins, 97 of which were statistically different (two tailed t-test, p<0.05) between the two groups. The Vascular Cell Adhesion Protein 1 (VCAM1, p<0.001) and Angiopoietin-related protein 4 (ANGPTL4, p<0.01) were constantly overexpressed in the success group. Both proteins are biologically relevant associated with the adhesion and ANGPTL4 is involved in angiogenesis and vascular leakage.Conclusions: Based on a unique biobank and clinical database, we have identified 2 therapeutic biomarkers that may stratify patients' management. These results require validation which is underway using a retrospective (TIME1 trial) and prospective (SIMPLE study) datasets.